GRACE is a Network of Excellence funded by the European Commission focusing on the complex and controversial field of community-acquired lower respiratory tract infections. This initiative, which counts with the support of IDIBAPS and Hospital Clínic of Barcelona, combats antimicrobial resistance through integrating centers of research excellence. The IDIBAPS team Applied research in infectious respiratory diseases, critically ill patients and lung cancer, led by Prof. Antoni Torres, participated in a work published by The Lancet showing that internet training achieved important reductions in antibiotic prescribing for respiratory-tract infections across language and cultural boundaries. More information leads to better treatment decisions.
Archive for the ‘Hospital Clínic’ Category
The Government of Catalonia and the Fundació Catalana per a la Recerca i la Innovació recognize through the 2013 National Research Awards the excellence in research activity of scientists. The awards want to encourage the social recognition of science and, particularly, to spread among the Catalan society the work of its researchers. These awards are the highest honour in research in Catalonia. The President of the Catalan Government, Artur Mas, underlined last night during the ceremony that “the path achieved in research, science and technology transfer” will allow the country, over the next ten years, “to talk face to face with the leading countries of the world”. This year’s winners were: Elías Campo, National Research Award; Isabelle Anguelovski, National Research Award to Young Talent; KIC InnoEnergy Iberia, National Award in Public- Private Partnership in Research and Innovation; José Carreras Foundation, National Award for scientific Sponsorship; and, Ara newspaper, National Award for Science Communication.
Information via: www.fundaciorecerca.cat
Sepsis is a generalized and exacerbated inflammatory reaction caused by a serious infection that could lead to multi-organ failure, shock and often death (30-50 % of cases). Increased antibiotic resistance, together with the fact that these drugs combat groups of bacteria but not the proinflammatory activity caused by them or their toxins, makes sepsis a disease orphan of effective therapies. A study published in the Journal of Infectious Diseases shows that CD6, a molecule from our own lymphocytes, could be an effective alternative or complement for antibiotics in cases of sepsis by both Gram-positive and Gram-negative bacteria, regardless they are resistant to antibiotics or producing lethal toxins. The work is the result of a academia-industry collaboration between the team led by Dr. Francisco Lozano, Senior Consultant at the Immunology Service of the Hospital Clínic and head of the IDIBAPS research team Immune receptors of the innate and adaptive system and at the University Barcelona, together with members of the R&D team at ImmunNovative Developments SL, a recently created spin-off which emerged based on patents generated by the aforementioned research group. The first authors of the study are Mario Martínez-Florensa and Marta Consuegra-Fernández.
The Lucie Bolte Foundation annually awards the Lucie Bolte Prize, the most important German prize for research in hepatology. On January 24, Dr. Pere Ginès, head of the Hepatology Service of the Hospital Clínic and investigator at the IDIBAPS team Pathophysiology and treatment of ascites and altered renal function in liver cirrhosis and professor of Medicine at the University of Barcelona, will receive the award during the Congress of the German Society for the Study of the Liver to be held in Tübingen. The award recognizes an important and ongoing experience in the field of liver cirrhosis, and for the first time it will received by a Spanish researcher.
Psychiatrists and basic scientists describe a dysregulation of the peripheral endocannabinoid system in first psychotic episodes
The journal Neuropsychopharmacology, from the Nature group, recently published an article that describes a dysregulation of the main components of the peripheral endocannabinoid system in patients with a first psychotic episode, comparing them with a large sample of healthy controls. After controlling for age, gender, body mass index, and cannabis use, the patient group showed a significantly reduced expression of the main enzymes of endocannabinoid synthesis and increased expression of those degrading them. The subgroup of patients with a history of cannabis showed a significant lower expression of some markers, compared with the control group. The first author of the study is Dr. Miquel Bioque and the last one is Dr. Miguel Bernardo, both members of the Schizophrenia Unit of the Hospital Clinic and the IDIBAPS team Biological bases of psychiatric disorders and nuclear psychiatry.
Cardiac-resynchronization therapy is not useful in patients with systolic heart failure and a narrow QRS
A work published in New England Journal of Medicine demonstrates how Cardiac-resynchronization therapy does not reduce the rate of death or hospitalization for heart failure, and may increase mortality, in patients with systolic heart failure and a QRS duration of less than 130 msec. The study was led from the Clinic for Cardiology at the University Hospital of Zurich (Switzerland), with Dr. Josep Brugada, head of the IDIBAPS team Arrhythmias, Resynchronization and Cardiac Imaging and Medical Director at Hospital Clínic of Barcelona, and Dr. Lluis Mont, from the same team, among its authors. Its results should allow a better use of the resynchronization therapy avoiding its use in patients in whom it is not indicated and even in some cases preventing a possible harm to the patient.